Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
N/A for expanded access
Drug: Selpercatinib
Open-label expanded access
Other Name: LOXO-292
Other Name: LY3527723
Inclusion Criteria: - Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib - Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy - Have adequate organ function
Exclusion Criteria: - Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor - Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Cancer Treatment Centers of America
Goodyear, Arizona, 85338
Contact: 623-207-3000
Investigator: Ashish Sangal
Mayo Clinic of Scottsdale
Scottsdale, Arizona, 85259
Contact: 480-301-8000
Investigator: Nina Karlin, MD
City of Hope National Medical Center
Duarte, California, 91010
Investigator: Erminia Massarelli
Contact: 626-256-4673
Investigator: Erminia Massarelli
University of California - San Diego
La Jolla, California, 92103
Contact: 858-534-2230
Investigator: Lyudmia Bazhenova
UCLA Medical Center
Los Angeles, California, 90095
Contact: 310-794-1816
Investigator: Mykola Onshchenko, MD
Kaiser Permanente
Oakland, California, 94612
Investigator: Jennifer Suga
Irvine Medical Center
Orange, California, 92868
Contact: 714-456-8000
Investigator: Viola Zhu
Kaiser Permanente Medical Center
Sacramento, California, 95814
Investigator: Jennifer Suga
Kaiser Permanente Medical Center
San Francisco, California, 94115
Investigator: Jennifer Suga
Univ of California San Francisco
San Francisco, California, 94115
Contact: 415-353-7552
Investigator: Alain Algazi
Kaiser Permanente
Santa Clara, California, 95051
Investigator: Jennifer Suga
UCLA Medical Center
Santa Monica, California, 90404
Contact: 310-633-9400
Investigator: Jonathan Goldman
Kaiser Permanente Medical Center
Vallejo, California, 94589
Contact: 510-891-3414
Investigator: Jennifer Suga
Memorial Cancer Institute
Hollywood, Florida, 33021
Investigator: Luis Raez
Contact: 305-243-1000
Investigator: Luis Raez
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224
Contact: 904-953-2000
Investigator: Victor Bernet, MD
Florida Hospital
Orlando, Florida, 32803
Contact: 407-303-0409
Investigator: Mark Socinski
Tallahassee Memorial Hospital
Tallahassee, Florida, 32308
Contact: 850-431-5360
Investigator: Karen Russell
University Cancer and Blood Center
Athens, Georgia, 30607
Contact: 706-353-2990
Investigator: Petros Nikolinakos
Emory University
Atlanta, Georgia, 30329
Contact: 404-727-6123
Investigator: Taofeek Owonikoko
University of Chicago Medicine-Comprehensive Cancer Center
Chicago, Illinois, 60637
Contact: 630-862-5757
Investigator: Christine Bestvina
Cancer Treatment Centers of America, Chicago
Zion, Illinois, 60099
Contact: 847-872-6324
Investigator: Eugene Ahn
Massachusetts General Hospital
Boston, Massachusetts, 02114
Contact: 617-726-2515
Investigator: Lori Wirth
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Contact: 617-632-5869
Investigator: Geoffrey Oxnard
University of Michigan
Ann Arbor, Michigan, 48109
Contact: 734-647-8902
Investigator: Francis Worden
START Midwest
Grand Rapids, Michigan, 49546
Contact: 616-954-5554
Investigator: Nehal Lakhani
Mayo Clinic
Rochester, Minnesota, 55905
Contact: 507-284-4080
Investigator: John Morris
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169
Contact: 702-952-3400
Investigator: Fadi Braiteh
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Contact: 646-888-4206
Investigator: Alexander Drilon
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Contact: 216-444-1128
Investigator: Nathan Pennell
Ohio State University Medical Center
Columbus, Ohio, 43210
Contact: 614-293-3873
Investigator: Manisah Shah
Cancer Treatment Centers of America
Tulsa, Oklahoma, 74133
Contact: 918-286-5689
Investigator: Issam Alawin
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
Investigator: Marcia Brose
Contact: 215-898-8796
Investigator: Marcia Brose
Eastern Regional Medical Center
Philadelphia, Pennsylvania, 19124
Contact: 215-537-4555
Investigator: Arturo Loaiza-Bonilla
Oncology Consultants
Houston, Texas, 77030
Contact: 713-797-6323
Investigator: Julio Peguero
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Contact: 713-745-6754
Investigator: Vivek Subbiah
Virginia Cancer Specialists
Fairfax, Virginia, 22031
Contact: 703-280-5390
Investigator: Alexander Spira
University of Wisconsin-Madison Hospital and Health Clinic
Madison, Wisconsin, 53792-4108
Investigator: Mark Burkard
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
ClinicalTrials.gov@lilly.com
Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Study Director
Eli Lilly and Company